You have to weigh the advantages of new and emerging products. For insulin, these include U300 insulin glargine, U500 insulin, and insulin degludec; while these agents expand therapeutic options, they also complicate decisions for many pharmacists. Now, pharmacists must consider not only administration, storage, and counseling, but also access.
Pharmacists are encouraged to take this quick quiz, in which an expert in the field will challenge you with five questions on new insulin products as it pertains to the learning objectives below.
At the completion of this knowledge-based activity, pharmacists will be able to:
1. Compare and contrast the characteristics of recently-approved forms of insulin.
2. Discuss effective educational strategies about safe and effective use of insulin.
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Activity Number for this activity is 0202-0000-17-117-H01-P.
To obtain 0.5 contact hour of CPE credit (0.05 CEUs) for "APhA Quick Quiz: New Insulin Products," complete the activity, evaluation questions, and CLAIM credit. Participants will need to have a valid pharmacist.com username and password to claim credit. After your credit has been claimed, please visit CPE monitor for your transcript.
Initial release date: March 1, 2017
Expiration date: March 1, 2020 - NO CREDIT GRANTED AFTER THIS DATE
"APhA Quick Quiz: New Insulin Products” is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.
Jennifer Trujillo, PharmD, BCPS, CDE, BC-ADM, FCCP, declares herself as an advisory board member in 2016 for Sanofi (consultant fee).
APhA’s editorial staff declares no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, please visit the APhA website at www.pharmacist.com/apha-disclosures .
Conflicts of interest have been resolved through content review by Helen Sairany, PharmD, BCACP, Associate Director of Content Development at the American Pharmacists Association.
Computer and Internet access is required to complete this activity. Please visit our website to view the System Requirements to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-17-117-H01-P||0.05 CEUs||March 01, 2017 - March 01, 2020|